{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:40:48Z","timestamp":1792294848185,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.09.012","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:10:36Z","timestamp":1792293036000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5486-749X","authenticated-orcid":false,"given":"Renil S.","family":"Titus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eusebio Luna","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vatsala","family":"Mundra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Riveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David-Dan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamuktha","family":"Porika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharam","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kershaw V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satkunasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.09.012_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0002","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","article-title":"Leuprolide versus diethylstilbestrol for metastatic prostate cancer","volume":"311","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000003721","article-title":"Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist","volume":"211","author":"Crawford","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0006","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/jco.2015.33.7_suppl.151","article-title":"Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: exploratory analysis of a randomized controlled trial","volume":"33","author":"Higano","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2026.09.012_bib0008","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0009","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41391-021-00483-5","article-title":"Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial","volume":"25","author":"Tiwari","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0012","article-title":"Comparative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists among patients diagnosed with prostate cancer: a systematic review and meta-analysis of real-world evidence studies","author":"Patel","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0013","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1080\/14796694.2025.2480050","article-title":"Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US","volume":"21","author":"Hafron","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36535","article-title":"Calibrating observational health record data against a randomized trial","volume":"7","author":"Merola","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0015","first-page":"1","article-title":"Comparative analysis of genitourinary toxicity following bladder outlet obstruction procedures in patients before versus after radiotherapy for localized prostate cancer: a retrospective cohort study using the TriNetX database","author":"Titus","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0016","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0017","unstructured":"scikit-learn. Machine learning in Python\u2014scikit-learn 1.9.0 documentation. https:\/\/scikit-learn.org\/stable\/. Accessed June 12, 2026."},{"key":"10.1016\/j.urolonc.2026.09.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9305","article-title":"Comparative outcomes of Empagliflozin to Dapagliflozin in patients with heart failure","volume":"7","author":"Modzelewski","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102306","article-title":"Safety and effectiveness of COVID-19 vaccines in patients with IgA nephropathy: a retrospective cohort study from the TriNetX global collaborative networks","volume":"65","author":"Chen","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0023","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0024","unstructured":"Monitoring your blood pressure at home.www.heart.org. https:\/\/www.heart.org\/en\/health-topics\/high-blood-pressure\/understanding-blood-pressure-readings\/monitoring-your-blood-pressure-at-home. Accessed March 21, 2025."},{"key":"10.1016\/j.urolonc.2026.09.012_bib0025","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1161\/01.CIR.0000141564.89465.4E","article-title":"Measurement of cholesterol","volume":"110","author":"Birtcher","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0026","unstructured":"American Heart Association. Monitoring lesser-known numbers in a blood screening can help heart health.https:\/\/www.heart.org\/en\/news\/2024\/01\/12\/monitoring-lesser-known-numbers-in-a-blood-screening-can-help-heart-health. Accessed March 21, 2025."},{"key":"10.1016\/j.urolonc.2026.09.012_bib0027","unstructured":"Body mass index in adults. www.heart.org. https:\/\/www.heart.org\/en\/healthy-living\/healthy-eating\/losing-weight\/bmi-in-adults. Accessed March 21, 2025."},{"issue":"13","key":"10.1016\/j.urolonc.2026.09.012_bib0028","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.30587","article-title":"Real-world cardiovascular outcomes associated with degarelix vs leuprolide for prostate cancer treatment","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0030","unstructured":"American Urological Association. Advanced prostate cancer: AUA\/SUO guideline. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/advanced-prostate-cancer. Accessed June 15, 2025."},{"key":"10.1016\/j.urolonc.2026.09.012_bib0031","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/UPJ.0000000000000557","article-title":"Patterns of care for Medicare beneficiaries with metastatic prostate cancer","volume":"11","author":"Filson","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0032","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/cncr.31297","article-title":"Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life","volume":"124","author":"Golan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0033","unstructured":"The American Heart Association. PREVENTTM online calculator.https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-calculator. Accessed June 13, 2025."},{"key":"10.1016\/j.urolonc.2026.09.012_bib0034","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/cncr.26623","article-title":"Androgen deprivation and thromboembolic events in men with prostate cancer","volume":"118","author":"Ehdaie","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.09.012_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23115","article-title":"Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US","volume":"6","author":"Kc","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:10:45Z","timestamp":1792293045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S1078143926007428"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}